Sam-A Pharm

Sam-A Pharm was established in 1973 as Sam-A Pharmaceutical Industry and listed on KOSDAQ in 2000.

Its main product categories include respiratory drugs, antibiotics, dermatological agents, gastrointestinal drugs, analgesics/anti-inflammatories, and cardiovascular/endocrine medicines, alongside over-the-counter products and health functional foods.

The business is notably concentrated in respiratory-category products, making revenue highly sensitive to seasonal factors and infectious disease trends. To reduce this concentration, the company has been diversifying its product portfolio by launching drugs in orthopedics, internal medicine, and urology.

Sales channels are split between prescription drugs sold through hospitals and clinics and over-the-counter products sold via pharmacies and consumers, in a competitive landscape shared with numerous small and mid-sized domestic pharmaceutical firms.

As a KOSDAQ small-cap with a market capitalization around KRW 90 billion, its scale of R&D investment and new-drug pipeline is limited relative to larger pharmaceutical peers. The controlling shareholder is CEO Heo Jun, son of the company's founder, with the family and related parties together holding a majority stake.

Consolidated revenue fell sharply to KRW 77.8 billion in 2025 from KRW 95.6 billion in 2024, while operating profit dropped by more than half to KRW 11.0 billion from KRW 24.5 billion.

As a result, operating margin declined sharply from 25.6% in 2024 to 14.1% in 2025, moving out of the roughly 20%-plus margin range maintained in 2023 (24.2%) and 2022 (22.3%). Net income also fell from KRW 22.1 billion in 2024 to KRW 12.9 billion in 2025.

Quarterly volatility is even more pronounced: after revenue of KRW 17.4 billion and operating profit of KRW 2.0 billion in Q2 2025, revenue slipped to KRW 15.1 billion in Q3, resulting in a temporary swing to an operating loss of KRW 1.1 billion and a marginal net loss.

The company then recovered in Q4 with revenue of KRW 20.8 billion, operating profit of KRW 2.7 billion, and net income of KRW 4.0 billion, followed by Q1 2026 (revenue KRW 17.6 billion, operating profit KRW 2.1 billion, net income KRW 2.2 billion) and Q2 2026 (revenue KRW 18.8 billion, operating profit KRW 1.9 billion, net income KRW 4.4 billion).

Notably, in Q2 2026 net income nearly doubled even as operating profit slightly declined from the prior quarter, suggesting non-operating factors contributed to the bottom-line improvement.

Over the trailing four quarters (Q3 2025 through Q2 2026), attributable net income totaled roughly KRW 10.5 billion, reflecting a trajectory in which the one-off loss in Q3 2025 was subsequently offset over the following three quarters.

On the cash flow side, 2025 operating cash flow of KRW 10.7 billion stayed close to net income of KRW 12.9 billion, indicating relatively stable earnings quality despite the margin compression.

The domestic small and mid-cap traditional pharmaceutical sector has been passing through a phase of weaker-than-usual respiratory infection trends in 2025-2026, which has broadly dampened demand for related treatments.

Indeed, other traditional pharmaceutical companies with similar product structures have also reported Q1 2026 revenue and operating profit declines year over year attributable to a respiratory demand gap.

On top of this, intensifying generic drug competition and government drug price cuts are exerting margin pressure across the industry, and Sam-A Pharm is reported to have faced a double burden of generic entry and price cuts on certain products.

Against this backdrop, many small and mid-sized pharmaceutical companies are pursuing strategies to broaden their revenue base through high-value new products in areas such as oncology and central nervous system treatments, along with production line diversification.

Sam-A Pharm's effort to expand into orthopedics, internal medicine, and urology aligns with this broader industry trend.

It is also a common feature across the sector that numerous pharmaceutical companies have been disclosing expanded dividend and shareholder-return plans in line with the government's corporate value-up policy stance.

That said, with annual revenue of roughly KRW 78 billion, Sam-A Pharm remains a small-cap player within the sector, with relatively limited capacity for new drug development and production infrastructure investment compared to larger pharmaceutical companies.

The company is pursuing product portfolio diversification through new drug launches in orthopedics, internal medicine, and urology to reduce its dependence on respiratory products, a factor cited as potentially easing seasonal revenue volatility going forward.

Having recovered from the temporary loss in Q3 2025 and sustained a profitable trend through Q1 and Q2 2026, whether this recovery trend continues into the second half remains a key point to monitor.

In its recently disclosed corporate value-up plan, the company presented stable profit generation and continued shareholder returns as core goals, and given the steady expansion of dividend payouts over the past three years, the sustainability of this dividend policy going forward is a point of attention from a shareholder-return perspective.

However, some observers have also raised concerns that expanding dividends even as net income declines could become a mid- to long-term financial burden.

No specific quantitative guidance on new product launch timing or expected sales contribution has yet been confirmed, warranting continued monitoring through future quarterly filings and disclosures.

On the balance sheet side, the debt ratio has remained low at around 10%, suggesting the company retains financial capacity to support both new product investment and dividend expansion.